Rentosertib Shifts Proteomic Aging-Clock Readouts
A Nature Biotechnology analysis applied six proteomic aging clocks to longitudinal serum samples from 42 participants in rentosertib’s randomized Phase IIa idiopathic pulmonary fibrosis trial. Treated groups generally shifted toward lower predicted biological age…
